Seres to sell bacterial infection drug to Nestle Health

Seres Therapeutics

06/06/2024 11:41

June 6 (Reuters) - Seres Therapeutics  MCRB.O  said on
Thursday it has entered into a non-binding memorandum of
understanding with Nestlé Health Science for the sale of its
bacterial infection drug and related intellectual property
rights. 

 (Reporting by Pratik Jain in Bengaluru; Editing by Nivedita
Bhattacharjee)
 ((Pratik.Jain@thomsonreuters.com;))